Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Path To Profitability
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Shares Fly 28% But Investors Aren't Buying For Growth
H.C. Wainwright Maintains Akebia Therapeutics(AKBA.US) With Buy Rating, Maintains Target Price $7.5
H.C. Wainwright analyst Ed Arce maintains $Akebia Therapeutics(AKBA.US)$ with a buy rating, and maintains the target price at $7.5.According to TipRanks data, the analyst has a success rate of 43.9%
Buy Rating Reaffirmed for Akebia Therapeutics Ahead of Vafseo's Market Launch
Express News | Akebia Therapeutics and U.S. Renal Care Initiate the Voice Trial of Vafseo® (Vadadustat) for Patients on Dialysis
Akebia Therapeutics and U.S. Renal Care Initiate the VOICE Trial of Vafseo (Vadadustat) for Patients on Dialysis
Express News | Akebia Therapeutics Inc Files for Mixed Shelf of up to $250 Mln - SEC Filing
Akebia Therapeutics Analyst Ratings
Express News | Akebia Therapeutics, Inc. : H.c. Wainwright Raises Target Price to $7.5 From $6
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Just Reported And Analysts Have Been Lifting Their Price Targets
Earnings Call Summary | Akebia Therapeutics(AKBA.US) Q2 2024 Earnings Conference
Akebia Therapeutics, Inc. (AKBA) Q2 2024 Earnings Call Transcript
Analysts Have Conflicting Sentiments on These Healthcare Companies: GeoVax Labs (GOVX), Akebia Therapeutics (AKBA) and Aveanna Healthcare Holdings (AVAH)
Akebia GAAP EPS of -$0.04, Revenue of $43.67M
Akebia Therapeutics | 10-Q: Q2 2024 Earnings Report
Earnings Flash (AKBA) AKEBIA THERAPEUTICS Posts Q2 Revenue $43.6M, Vs. Street Est of $43.7M
Akebia Therapeutics Q2 2024 GAAP EPS $(0.04) Beats $(0.05) Estimate, Sales $43.648M Miss $49.450M Estimate
Express News | Akebia Therapeutics Q2 Net Income USD -8.582 Million
Express News | Akebia Therapeutics Q2 Operating Expenses USD 35.326 Million
Press Release: Akebia Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights